Phase 2 Alzheimer's Disease Trial, Recruiting NCT07496918 Sponsor: Massachusetts Institute of Technology Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT07496918
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People with sufficient vision and hearing to be able to see and hear the test materials used during the study.
  • People who are able to complete psychological and memory-style testing and other study tasks, in the opinion of the trial doctor.

Who may not be able to join:

  • People with a history of seizures or a diagnosis of epilepsy.
  • People who cannot have an MRI scan due to having certain metal devices or objects in or on their body, such as a pacemaker, aneurysm clips, an artificial heart valve, ear implants, or metal fragments in the eyes, skin, or body.
  • People where the trial doctor believes completing the key parts of the study would not be possible. The trial team notes that exceptions to this may be considered on a case-by-case basis by the Project Director.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ana Trisini Lipsanopoulos, BS, Massachusetts Institute of Technology

Phone: 617-258-7723

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Massachusetts Institute of Technology
Registry
ClinicalTrials.gov
Start date
20 February 2018
Est. completion
30 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Effects of GENUS on brain oscillations; Effects of GENUS on brain oscillations; Effects of GENUS on brain oscillations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov